Form 4: MoonLake Immunotherapeutics Director Acquires Options
SEC Form 4
Director Andrew John Phillips acquired options to purchase 7,688 Class A Ordinary Shares in MoonLake Immunotherapeutics on June 6, 2024.
Summary
- On June 6, 2024, Andrew John Phillips, a director of MoonLake Immunotherapeutics, acquired options to buy 7,688 Class A Ordinary Shares.
- The exercise price of the options is $42.44.
- The options vest on the earlier of June 6, 2025, the date of the next annual general meeting, or a change in control, contingent on continued service to the Issuer.
- The options expire on June 6, 2034.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock options, so it doesn't significantly impact sentiment.
Industry Context
This is a standard disclosure related to executive compensation and is common in the biopharmaceutical industry.
Stakeholder Impact
- The acquisition of options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of the options transaction. |
| 06/06/2025 | Earliest vesting date for the options. |
| 06/06/2034 | Expiration date of the options. |
| 06/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.